Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1130

2.

Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.

Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.

BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13.

3.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ.

J Sex Med. 2012 Jan;9(1):271-81. doi: 10.1111/j.1743-6109.2011.02504.x. Epub 2011 Oct 7.

PMID:
21981682
4.

Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.

Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L.

J Sex Med. 2015 Jan;12(1):129-38. doi: 10.1111/jsm.12714. Epub 2014 Oct 29.

PMID:
25353053
6.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12.

PMID:
21871706
7.

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.

Urology. 2013 Sep;82(3):667-73. doi: 10.1016/j.urology.2013.05.005. Epub 2013 Jul 19. Erratum in: Urology. 2014 Mar;83(3):684.

PMID:
23876588
8.

Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.

Brock GB, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C.

J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1.

PMID:
24096120
10.

Tadalafil - a therapeutic option in the management of BPH-LUTS.

Carson CC, Rosenberg M, Kissel J, Wong DG.

Int J Clin Pract. 2014 Jan;68(1):94-103. doi: 10.1111/ijcp.12305. Review.

PMID:
24341303
12.

Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.

Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC.

BJU Int. 2016 Jul;118(1):153-60. doi: 10.1111/bju.13406. Epub 2016 Feb 11.

13.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.

Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16.

PMID:
20163842
14.

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.

Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.

PMID:
22297243
15.

Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.

Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H.

J Sex Med. 2008 Sep;5(9):2170-8. doi: 10.1111/j.1743-6109.2008.00940.x. Epub 2008 Jul 14.

PMID:
18638006
16.

Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.

Chapple CR, Roehrborn CG, McVary K, Ilo D, Henneges C, Viktrup L.

Eur Urol. 2015 Jan;67(1):114-22. doi: 10.1016/j.eururo.2014.08.072. Epub 2014 Oct 7.

PMID:
25301757
17.

Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.

Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L.

J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2.

PMID:
24096118
18.

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.

Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, Morisaki Y, Viktrup L.

Int J Urol. 2013 Feb;20(2):193-201. doi: 10.1111/j.1442-2042.2012.03130.x. Epub 2012 Sep 7.

20.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.

J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.

PMID:
18722631

Supplemental Content

Support Center